Renalytix AI PLC Podium Presentation and Publication for Data
24 March 2020 - 6:00PM
RNS Non-Regulatory
TIDMRENX
Renalytix AI PLC
24 March 2020
Renalytix AI plc
("RenalytixAI", the "Company")
Podium Presentation and Publication for Health Economics
Data
Presentation titled: Evaluation of Payer Budget Impact
Associated with the Use of Artificial Intelligence in vitro
Diagnostic, KidneyIntelX(TM), to Modify DKD Progression
Oral presentation accepted for Late Breaking session of the
National Kidney Foundation Spring Clinical Meeting
Accompanying abstract accepted for publication in American
Journal of Kidney Disease
Renalytix AI plc (LSE : RENX), the AIM-traded developer of
clinical grade artificial intelligence in vitro diagnostics for
kidney disease, announces that data from a study highlighting the
health economic benefits associated with KidneyIntelX(TM) testing
in diabetic kidney disease populations (DKD) will be presented at
the National Kidney Foundation Spring Clinical Meeting being held
in the United States. An abstract summarizing key results will be
published in the peer reviewed journal, the American Journal of
Kidney Disease.
National Kidney Foundation Spring Clinical Meeting (26 March
2020)
Thomas Goss, PharmD, Senior Vice President, Boston Healthcare
Associates, will deliver a presentation titled Evaluation of Payer
Budget Impact Associated with the Use of Artificial Intelligence in
vitro Diagnostic, KidneyIntelX(TM), to Modify DKD Progression
during the Late Breaking Abstract session at the National Kidney
Foundation's Spring Clinical Meeting. The presentation will
highlight t he significant cost savings associated with the
implementation of KidneyIntelX(TM) in large health care system
patient populations in the United States. The presentation is based
on a comprehensive economic model developed by Boston Healthcare
Associates utilizing peer reviewed clinical data to estimate the
costs associated with chronic kidney disease progression in the
U.S. The presentation session will be held on Thursday, 26 March
2020 at 4:15 PM ET. A summary of the presentation results will be
made available on the Company's website.
Thomas Goss, Senior Vice President at Boston Healthcare
Associates Inc, commented: "The results suggest substantial cost
savings can be achieved using KidneyIntelX(TM) to assess CKD
patient populations at risk of rapid kidney function decline and/or
kidney failure under a number of different scenarios tested."
An abstract summarizing the results will also be published in
the May 2020 issue of the American Journal of Kidney Disease (
www.ajkd.org ) , the official journal of the National Kidney
Foundation, which is recognized worldwide as a leading source of
information devoted to clinical nephrology practice and clinical
research.
NKF's Spring Clinical Meeting gathers more than 3,000 nephrology
healthcare professionals from across the United States to learn
about the newest developments related to all aspects of nephrology
practice. Due to the coronavirus and coronavirus disease (COVID-19)
outbreak in the United States the meeting is being held as a live
virtual event in 2020. Sessions can be accessed through the
conference website.
For further information, please contact:
Renalytix AI plc www.renalytixai.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser & Joint Broker) Tel: 020 7710 7600
Alex Price / Jonathan Senior / Ben Maddison
N+1 Singer (Joint Broker) Tel: 020 7496 3000
Aubrey Powell / George Tzimas (Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391
303
About Kidney Disease
Kidney disease is now recognised as a public health epidemic
affecting over 850 million people globally. The Centers for Disease
Control and Prevention (CDC) estimates that 15% of US adults, or 37
million people, currently have chronic kidney disease (CKD).
Further, the CDC reports that 9 out of 10 adults with CKD do not
know they have it and 1 out of 2 people with very low kidney
function who are not on dialysis do not know they have CKD*. Kidney
disease is referred to as a "silent killer" because it often has no
symptoms and can go undetected until a very advanced stage. Each
year kidney disease kills more people than breast and prostate
cancer. Every day, 13 patients in the United States die while
waiting for a kidney transplant.
*
https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About RenalytixAI
RenalytixAI is a developer of clinical grade, artificial
intelligence-enabled in vitro diagnostic solutions for kidney
disease, one of the most common and costly chronic medical
conditions globally. The Company's products are being designed to
make significant improvements in kidney disease diagnosis,
transplant management, clinical care, and patient stratification
for drug clinical trials. For more information, visit
renalytixai.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAJJMMTMTATTRM
(END) Dow Jones Newswires
March 24, 2020 03:00 ET (07:00 GMT)
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024